2023 Company Report

chairman’s message
Stefan Meister Chairman of the Board of Directors

2023 was a landmark year for Stallergenes Greer. The Group continued to fulfil its mission of improving the quality of life of people with allergies while creating sustainable growth.

Throughout the year, Stallergenes Greer made significant progress on its strategic roadmap with the entry into the field of food allergy with Palforzia®, the expansion of its geographic footprint and the launch of products and services in new regions. The addition of Palforzia®, the only approved oral immunotherapy treatment for peanut allergy, to Stallergenes Greer’s portfolio marks an important milestone for the Group which is the only player present in both food and respiratory allergy. It is also testimony to Stallergenes Greer’s long-term commitment to providing patients with effective treatment solutions for an everexpanding range of allergic conditions.

These achievements were made possible by the focus and dedication of Stallergenes Greer’s employees. On behalf of the Board of Directors, I would like to express my gratitude to all the Group’s employees who, under the leadership of Michele Antonelli, have contributed to building a resilient and innovative Stallergenes Greer.

With solid fundamentals, robust and agile operations, and a relentless drive for innovation, Stallergenes Greer is well-equipped to continue shaping the future of allergen immunotherapy for the benefit of patients and the medical community.

interview with our CEO
Michele Antonelli Chief Executive Officer

How did Stallergenes Greer perform in 2023 and what were the main challenges and highlights of the year?

2023 was an exciting and busy year for Stallergenes Greer, marked by significant advancements in all areas. We posted robust commercial performance across all geographies: our North American operations showed consistent growth of core activities; the Europe and International region expanded its geographic footprint while successfully launching Orylmyte®; and France increased its market share and captured 30% of new prescriptions for Orylmyte®, barely a year after launch.

Another major highlight of the year was the agreement with Nestlé regarding Palforzia®. With the addition of Palforzia® to our portfolio, Stallergenes Greer now provides a clinically proven oral immunotherapy treatment for peanut allergy. This step forward in the food allergy space holds promise for people suffering from food allergy.

The year was also one of progress in the clinical field, in both respiratory and food allergies. Our European Phase III YOBI study (Young Patients and Birch Allergy), to analyse the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma, is moving forward as planned.

In China, important strides were made with the completion of our clinical design study for Actair® and the submission of our investigational new drug dossier to the National Medical Products Administration. And, the Phase III Poseidon (Peanut Oral Immunotherapy Study of Early Intervention) study results, which evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years, were published.

I am proud of our performance and of the engagement of our people who contributed to make 2023 another year of success.

The Group is now present in food allergy. What are your ambitions in this field?

We made our first step in food allergy with the addition of Palforzia® to our portfolio and firmly intend to further invest in this field. Often, when a person is tested for peanut allergy, the first recommendation of physicians is peanut avoidance. Although a peanut avoidant diet is necessary, it is not a treatment! The lives of people with peanut allergy remain at risk of anaphylaxis in the event of accidental exposure.

Our ambition is to make more treatments available, treatments which mitigate adverse reactions and complement avoidance measures. With our entry in the food allergy space, we are further developing our competencies and leveraging our scientific network to tackle other food allergens, such as nuts as well as other foods, which represent a true burden on society.

In large markets such as China, Europe, Japan and the U.S., parents and children are faced with an unmet medical need and are hoping for solutions to treat food allergy. We can also expect that treating these allergies will not only improve the quality of life of people affected by them, but also have a significant impact on the costs associated with the burden of disease for society.

The state of research has evolved significantly over the past decade, what are the main trends to further improve the quality of life of people with allergies?

Research in the allergy field is evolving at a rapid pace. One of the trends we are seeing is the development of monoclonal antibodies which block the inflammation cascade responsible for allergy symptoms. Patients who discontinue monoclonal antibody therapy may, however, experience a relapse. And, observation of these antibodies shows that when treatment is stopped, allergy symptoms are exacerbated, which unfortunately means that the disease is not treated. Current research is investigating the combination of monoclonal antibodies with allergen immunotherapy, which could potentially improve treatment outcomes.

In my view, another significant opportunity lies in deepening our understanding of the role of allergens in the pathophysiology of allergies and their resolution. We must understand which allergens trigger the immune system response for effective treatment, as well as those that may cause adverse reactions. Clinical assessments of allergen groups are essential to inform the development of new treatment options.

Precision medicine must also be leveraged to treat allergies. By precisely targeting molecules and understanding the clinical impact of treatment, we can help physicians treat each patient more precisely.

Each patient is different, with his or her individual profile, and treatment should be adapted to each profile and specific need. This is an area in which Stallergenes Greer has solid competencies, and one in which the Group benefits from a wealth of data to adapt treatment effectively.

In the future, how will Stallergenes Greer maintain its growth momentum and continue contributing to society?

Moving forward, we will continue to invest our efforts in food allergy and in the generation of new data to further develop and manage the lifecycle of our therapeutic offer with new solutions.

For example, we have a product which we will continue to grow, more specifically in the paediatric space, thanks to dosage flexibility and the use of our connected delivery system which aims to enhance treatment adherence and compliance.

As a responsible corporate citizen and a world leader in allergen immunotherapy, it is our duty to contribute to sustaining the environment for future generations.

We are committed to lessening our impact by producing and distributing drugs with a minimal effect on the environment in terms of waste, energy consumption, pollution, and greenhouse gas emissions. And, through the Stallergenes Greer Foundation, which awarded its first Science Awards for Allergy in May 2024, we notably engage in climate action and environmental protection to progress the prevention and treatment of allergies.